Where it trades today
trading 85% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- Recent realized volatility is running around 597.5%, above the sector norm of 22.0%, so position sizing matters more than usual.
- MRNA is in a bullish short-term regime and only 12.8% below its 52-week high, so the question is whether fundamentals can keep pace with that stronger tape.
Portfolio Use Case
- MRNA is more useful for investors comparing conviction names inside healthcare than for someone looking for a passive “set and forget” holding.
- The risk profile looks balanced enough for a diversified core-plus portfolio, provided the position size reflects sector concentration.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- If the short-term trend rolls over while volume fades, the market may stop paying up for momentum before the fundamentals change.
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- There is little income cushion here, so total return depends mainly on price appreciation and execution staying on track.
Methodology
- Price, market cap, beta, yield, and liquidity fields for MRNA come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for MRNA. Last refresh: Sep 18, 2026, 10:57 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Moderna Inc. does
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products,…
What analysts expect
MRNA carries a hold consensus from 18 analysts, with an average price target of $119.56 versus $154.04 today (-22.4%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
MRNA generated $2.23B in trailing revenue (2.1% year over year), with a -141.4% net margin, and $299.25M of free cash flow, supported by $3.85B of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $1.92B | $1.05B | -$3.07B | -$2.82B | -$7.26 | -$2.08B |
| 2024 | $3.20B | $1.74B | -$3.94B | -$3.56B | -$9.28 | -$4.05B |
| 2023 | $6.75B | $2.06B | -$4.24B | -$4.71B | -$12.33 | -$3.83B |
| 2022 | $18.88B | $13.46B | $9.42B | $8.36B | $21.26 | $4.58B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
MRNA beside the healthcare names it is usually measured against.
What the chart is saying
Moderna Inc. trades at $154.04, 12.8% below its 52-week high. With a beta of 1.11, it shows about average sensitivity to what the wider market does.
Questions people ask about it
Is MRNA a good buy right now?
Moderna Inc. operates in the Healthcare sector. Current risk level is Very High based on 597.5% volatility.
Does MRNA pay dividends?
Moderna Inc. does not currently pay a regular dividend. The company may be reinvesting profits for growth.
How volatile is MRNA?
With 30-day annualized volatility of 597.5% and beta of 1.11, MRNA is classified as Very High risk. Expect larger swings than the broader market during volatile periods.
What is the analyst price target for MRNA?
The average analyst price target for Moderna Inc. (MRNA) is $119.56 based on 18 analyst estimates, about 22.4% below the current price of $154.04. The published range runs from $45.00 to $170.00.
How much revenue does MRNA generate?
Moderna Inc. reported $2.23B in trailing twelve-month revenue. Revenue growth is running at 2.1% year over year. Net margin sits at -141.4%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.